Bristol?s Opdivo reduces risk of death from common lung cancer

[ahlam1399]

Bristol?s Opdivo reduces risk of death from common lung cancer
Chicago (Reuters) - Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday.http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/46c4837d/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Lf4rSFgNssw:KRIB86pxhGc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Lf4rSFgNssw:KRIB86pxhGc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Lf4rSFgNssw:KRIB86pxhGc:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Lf4rSFgNssw:KRIB86pxhGc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Lf4rSFgNssw:KRIB86pxhGc:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Lf4rSFgNssw